Ratnakar Securities Pvt. Ltd.

SUPRIYA LIFESCIENCE LTD.

NSE : SUPRIYABSE : 543434ISIN CODE : INE07RO01027Industry : Pharmaceuticals & DrugsHouse : Private

BSE681.5025.45 (+3.88 %)

PREV CLOSE ( ) 656.05

OPEN PRICE ( ) 656.05

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 22162

TODAY'S LOW / HIGH ( )649.25 685.20

52 WK LOW / HIGH ( )368.6 841.7

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 26-03 2008

Management Info

Satish Waman Wagh - Chairman Saloni Satish Wagh - Managing Director

Registered Office

Address 207/208, Udyog Bhavan,Sonawala Road,Goregaon (East),
Mumbai,
Maharashtra-400063

Phone 022-40332727

Email supriya@supriyalifescience.com

Website www.supriyalifescience.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

24Apr Supriya Lifescience informs about outc
Supriya Lifescience has informed that as set out in the Notice of Postal..

24Apr Supriya Lifescience informs about scru
Supriya Lifescience has informed that it enclosed the voting results of..

10Mar Supriya Lifescience informs about boar
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..

01Feb Supriya Lifescience informs about reti
Supriya Lifescience has informed that Kedar Karmarkar (Din No.:06499019)..

25Jan Supriya Lifescience informs about pres
Supriya Lifescience has informed that the Board of Directors of the Comp..

Financials

in Millions

	QTR Mar 25	ANNUAL 25
Net Profit	503.82	1879.58
Gross Profit	640.62	2484.81
Operating Profit	705.6	2706.11
Net Sales	1841.09	6964.85

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE) 31529.10 (1.67%)	M.Cap ( in Cr)66997.14
Sanofi Cons. Health (BSE) 5075.20 (2.17%)	M.Cap ( in Cr)11688.50
JB Chem & Pharma (BSE) 1771.25 (5.98%)	M.Cap ( in Cr)27657.06
Divi's Lab (BSE) 6589.85 (1.49%)	M.Cap ( in Cr)174939.81
Wockhardt (BSE) 1730.65 (2.58%)	M.Cap ( in Cr)28120.56

Shareholding Pattern

	PROMOTERS	68.3%
	NON-INSTITUTION	20.26%
	FI/BANKS/INSURANCE	1.7%
	MUTUAL FUNDS/UTI	0.66%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Quantum Small Cap F...	3.19
ITI Large & Mid Cap...	2.03
ITI ELSS Tax Saver ...	1.78
ITI Pharma & Health...	1.71
WOC Pharma and Heal...	1.27
Motilal Oswal Nifty...	0.28

attention investors
kyc
ipo
ibt trading
KYC & KRA Status Awareness

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

SUPRIYA LIFESCIENCE LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES